Difference between revisions of "Rivaroxaban (Xarelto)"
Warner-admin (talk | contribs) m (Text replacement - "[[Venous thromboembolism (VTE)" to "[[Venous_thromboembolism") |
m |
||
| Line 11: | Line 11: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*Atrial fibrillation | *Atrial fibrillation | ||
| − | *[[ | + | *[[Venous thromboembolism]] |
==Patient drug information== | ==Patient drug information== | ||
| Line 18: | Line 18: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *7/1/2011: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm261839.htm FDA approved] | + | *7/1/2011: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm261839.htm FDA approved] for the prophylaxis of [[Venous thromboembolism|DVT]], which may lead to PE in patients undergoing knee or hip replacement surgery. |
| − | *11/4/2011: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm FDA approved] | + | *11/4/2011: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm FDA approved] to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ''(Non-hematologic indication)'' |
| − | *11/2/2012: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm FDA approved] for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE. | + | *11/2/2012: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm FDA approved] for the treatment of [[Venous thromboembolism|deep vein thrombosis (DVT), pulmonary embolism (PE)]], and for the reduction in the risk of recurrence of DVT and of PE. |
==Also known as== | ==Also known as== | ||
Revision as of 12:55, 8 May 2021
General information
Class/mechanism: Factor Xa inhibitor, acts at the active site of factor Xa to inhibit its actions in the coagulation cascade.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Reversal information
Factor Xa, recombinant, inactivated-zhzo (Andexxa) can bind, sequester, and reverse the anticoagulation effect of rivaroxaban and apixaban.
Diseases for which it is used
- Atrial fibrillation
- Venous thromboembolism
Patient drug information
- Rivaroxaban (Xarelto) package insert[1]
- Rivaroxaban (Xarelto) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/1/2011: FDA approved for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.
- 11/4/2011: FDA approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (Non-hematologic indication)
- 11/2/2012: FDA approved for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE.
Also known as
- Code name: BAY 59-7939
- Brand name: Xarelto